Ginkgo Bioworks Holdings, Inc.

NYSE:DNA 株式レポート

時価総額:US$407.2m

Ginkgo Bioworks Holdings マネジメント

マネジメント 基準チェック /34

Ginkgo Bioworks Holdingsの CEO はJason Kellyで、 Jan2008年に任命され、 の在任期間は 16.83年です。 の年間総報酬は$ 262.50Kで、 95.2%給与と4.8%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の3.84%を直接所有しており、その価値は$ 15.63M 。経営陣と取締役会の平均在任期間はそれぞれ6.3年と2.7年です。

主要情報

Jason Kelly

最高経営責任者

US$262.5k

報酬総額

CEO給与比率95.2%
CEO在任期間16.8yrs
CEOの所有権3.8%
経営陣の平均在職期間6.3yrs
取締役会の平均在任期間2.7yrs

経営陣の近況

Recent updates

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Nov 15
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Ginkgo Bioworks: Not Enough Progress

Nov 13

Revenues Tell The Story For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) As Its Stock Soars 33%

Oct 04
Revenues Tell The Story For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) As Its Stock Soars 33%

Ginkgo Bioworks: Here Comes The Test

Aug 22

The Price Is Right For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Even After Diving 27%

Aug 16
The Price Is Right For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Even After Diving 27%

Ginkgo Bioworks: Losing A Major Supporter

Jun 25

Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 47% Slump

Jun 18
Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 47% Slump

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

May 11
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Ginkgo Bioworks: Broken Narrative

May 10

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing

Apr 26
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing

Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts

Mar 06
Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts

With Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) It Looks Like You'll Get What You Pay For

Mar 01
With Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) It Looks Like You'll Get What You Pay For

Ginkgo Bioworks: More Awful Revenue Guidance

Mar 01

Ginkgo Bioworks At The Intersection Of Cutting-Edge Technology And Financial Disappointment

Jan 26

Ginkgo Bioworks: Strategic Shifts Amidst Financial Uncertainty

Dec 20

Ginkgo Bioworks: A Long Way To Go

Nov 21

News Flash: 9 Analysts Think Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Earnings Are Under Threat

Nov 13
News Flash: 9 Analysts Think Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Earnings Are Under Threat

Ginkgo Bioworks: More Revenue Issues

Nov 13

Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 30% Slump

Nov 10
Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 30% Slump

Porter's 5 Forces Suggest That Ginkgo Is A Buy

Oct 25

Ginkgo Bioworks: Products Progressing Towards Market

Oct 10

Ginkgo Bioworks: Google Partnership Increases Runway (Rating Upgrade)

Aug 30

Ginkgo Bioworks: Lack Of Progress Is A Concern

Aug 18

Ginkgo Bioworks: Major Revenue Trouble (Ratings Downgrade)

Aug 10

Ginkgo Bioworks: Tremendous Potential, But Strong Short Term Headwinds

Jun 23

Ginkgo Bioworks: Avoid For Now

Feb 20

Ginkgo: Standardizing Offerings For Growth

Feb 08

Ginkgo Bioworks: Increasing Focus On Pharma And Biotech

Jan 12

CEO報酬分析

Ginkgo Bioworks Holdings の収益と比較して、Jason Kelly の報酬はどのように変化したか?
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$651m

Jun 30 2024n/an/a

-US$898m

Mar 31 2024n/an/a

-US$854m

Dec 31 2023US$263kUS$250k

-US$893m

Sep 30 2023n/an/a

-US$857m

Jun 30 2023n/an/a

-US$1b

Mar 31 2023n/an/a

-US$2b

Dec 31 2022US$263kUS$250k

-US$2b

Sep 30 2022n/an/a

-US$4b

Jun 30 2022n/an/a

-US$3b

Mar 31 2022n/an/a

-US$2b

Dec 31 2021US$381mUS$250k

-US$2b

Sep 30 2021n/an/a

-US$276m

Jun 30 2021n/an/a

-US$200m

Mar 31 2021n/an/a

-US$175m

Dec 31 2020US$11mUS$250k

-US$127m

報酬と市場: Jasonの 総報酬 ($USD 262.50K ) は、 US市場 ($USD 2.18M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Jasonの報酬は、過去 1 年間の会社の業績と一致しています。


CEO(最高経営責任者

Jason Kelly (43 yo)

16.8yrs

在職期間

US$262,500

報酬

Dr. Jason Kelly serves as Director of Genomatica, Inc. Dr. Kelly founded Ginkgo Bioworks, Inc. (nka:Ginkgo Bioworks Holdings, Inc.) in 2008 and serves as its Chief Executive Officer and has been Director s...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Jason Kelly
Founder16.8yrsUS$262.50k3.84%
$ 15.6m
Reshma Shetty
Founder16.8yrsUS$262.50k4.18%
$ 17.0m
Mark Dmytruk
Chief Financial Officer4yrsUS$1.69m0.084%
$ 343.8k
Thomas Knight
Founderno dataデータなしデータなし
Austin Che
Founderno dataデータなし4.28%
$ 17.4m
Bartholomew Canton
Founderno dataデータなし4.17%
$ 17.0m
Steven Coen
Chief Accounting Officer1.5yrsデータなし0.012%
$ 47.2k
Karen Tepichin
General Counsel & Secretaryno dataデータなしデータなし
Anna Wagner
Senior Vice President of Corporate Developmentno dataデータなしデータなし
Samantha Sutton
Head of People6.8yrsデータなしデータなし
Joshua Dunn
Head of Design6.1yrsデータなしデータなし
Joaquim Marques
Head of Omics & Analytical Chemistry6.3yrsデータなしデータなし

6.3yrs

平均在職期間

43yo

平均年齢

経験豊富な経営陣: DNAの経営陣は経験豊富で経験豊富です(平均在職期間は6.3年)。


取締役

名称ポジション在職期間報酬所有権
Jason Kelly
Founder16.8yrsUS$262.50k3.84%
$ 15.6m
Reshma Shetty
Founder16.8yrsUS$262.50k4.18%
$ 17.0m
Norbert Bischofberger
Member of Biopharma Advisory Boardless than a yearデータなしデータなし
John M. Maraganore
Member of Biopharma Advisory Boardless than a yearデータなしデータなし
Harry Sloan
Independent Director3.2yrsUS$459.38k0.037%
$ 150.6k
Mark McCamish
Member of Biopharma Advisory Boardless than a yearデータなしデータなし
Christian O. Henry
Independent Director8.8yrsUS$477.50k0.060%
$ 244.8k
Kathy Hannan
Independent Director2.3yrsUS$448.67k0.0075%
$ 30.5k
Arie Belldegrun
Independent Director3.2yrsUS$457.50k0.031%
$ 127.0k
Shyam Sankar
Independent Chairman of the Board9.8yrsUS$485.19k0.11%
$ 450.0k
Jeff Legos
Member of Biopharma Advisory Boardless than a yearデータなしデータなし
Paolo Martini
Member of Biopharma Advisory Boardless than a yearデータなしデータなし

2.7yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: DNAの 取締役会経験豊富 ではない ( 2.7年の平均在任期間) ため、新しい取締役会が必要であると考えられます。